Profund Advisors
RAPP icon

Profund Advisors’s Rapport Therapeutics RAPP Stock Holding History

Profund Advisors’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.11M Buy
33,112
+26,754
+421% +$1.15M 0.03% 332
2026
Q2 		$265K Buy
+6,358
New +$234K 0.01% 887
2026
Q1 		– Sell
-8,880
Closed -$269K – 1313
2025
Q4 		$269K Buy
+8,880
New +$246K 0.01% 954

Other funds holding RAPP

Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Sigma Planning Corp
Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Catalyst Private Wealth
Catalyst Private Wealth San Mateo, California $239M AUM 21.76% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
GF Fund Management
GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return
State of Wyoming
State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return

Profund Advisors's RAPP Position: Q3 2026 in Review

Profund Advisors increased its Rapport Therapeutics (RAPP) stake by 421% in Q3 2026, buying an estimated $1.15M and bringing the position to 33,112 shares worth $1.11M. The position accounts for 0.03% of the portfolio, ranked #332.

Profund Advisors first reported a position in RAPP in Q4 2025 and has held it in 3 quarters since. 31 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

  • Profund Advisors held 33,112 shares of Rapport Therapeutics worth $1.11M as of Q3 2026.
  • Profund Advisors bought 26,754 Rapport Therapeutics shares in Q3 2026, an estimated $1.15M.
  • Rapport Therapeutics made up 0.03% of Profund Advisors's portfolio in Q3 2026, its #332 holding.
  • Profund Advisors first reported a position in Rapport Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 31 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Profund Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.